HomeMost PopularInvestingAcadia Pharmaceuticals Takes on the Fight Against Alzheimer's Disease Psychosis

Acadia Pharmaceuticals Takes on the Fight Against Alzheimer’s Disease Psychosis

Actionable Trade Ideas

always free

Breaking the shackles of the medical status quo, Acadia Pharmaceuticals Inc. refuses to play second fiddle as it unshackles its innovative candidate, ACP-204, in a relentless onslaught against Alzheimer’s disease psychosis (ADP).

Following a blistering start, Acadia Pharmaceuticals Inc. ACAD announced the commencement of a mid-stage study to evaluate the safety and efficacy of its trailblazing candidate, ACP-204, in addressing the harrowing labyrinth of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).

The innovative ACP-204, with its revolutionary mechanism of action, primarily acts as an inverse agonist at the 5-HT2Areceptor. Yanking the rug from under the feet of the status quo, Acadia has set its crosshairs on a monumental medical challenge, as there are presently no FDA-approved treatments for ADP.

Marking the dawn of a new era in Alzheimer’s treatment, the commencement of the phase II study is merely the starter’s pistol for the planned phase II/III clinical program for ACP-204. This formidable mid-late-stage program comprises a single phase II study and two phase III studies, all boasting almost identical designs, cementing Acadia’s unyielding resolve to make a splash in the treatment of ADP.

Showcasing its mettle, Acadia’s shares have soared an incredible 39% year to date while the industry floundered under a crippling 23.8% decline.

Zacks Investment Research
Image Source: Zacks Investment Research

The energized mid-stage study is all set to draw in approximately 318 ADP patients and will assess treatment with two doses of ACP-204 (30 mg and 60 mg) against a placebo. The primary endpoint of the phase II study is the change from baseline in the Scale for the Assessment of Positive Symptoms–Hallucinations and Delusions subscales total score in the sixth week.

Post the phase II leg of the mid-late-stage clinical program for ACP-204, patients who qualify will proceed to phase III, where Acadia anticipates enrolling about 378 ADP patients for each of the planned phase III studies.

This is a landmark day, with Acadia also extending a lifeline to those who complete the phase III studies by offering the option to participate in a long-term open-label extension study.

According to the Alzheimer’s Association, more than 6.5 million people in the United States are grappling with Alzheimer’s disease, and an alarmingly high 30% of these patients confront the grim specter of psychosis, often manifesting through hallucinations and delusions.

The symptoms of ADP, which are oftentimes frequent and severe, inflict a heavy toll on the quality of life of those afflicted, and in extreme cases, psychosis in patients with dementia has led to tragic fatalities.

Acadia’s track record boasts the marketing of the inaugural FDA-approved treatment for hallucinations and delusions associated with Parkinson’s disease psychosis, Nuplazid (pimavanserin), which stormed onto the U.S. market in May 2016.

The indefatigable ACAD is simultaneously exploring Nuplazid’s potential in addressing schizophrenia-negative symptoms, reinforcing its commitment to unearthing solutions to medical challenges that have long been under the radar.

ACADIA Pharmaceuticals Inc. Price and Consensus

Mining for promising stock prospects, Acadia currently flaunts a Zacks Rank #2 (Buy).

Other notable stocks on the radar are Puma Biotechnology, Inc.  PBYI, ADMA Biologics ADMA, and Agenus AGEN. While PBYI boasts a Zacks Rank #1 (Strong Buy), ADMA and AGEN each hold a Zacks Rank #2 at present.

Revel in the abundance of top-tier options with the complete list of today’s Zacks #1 Rank stocks here.

Puma Biotech’s 2023 earnings per share has seen a promising upward shift, while ADMA and Agenus have also witnessed favorable changes in their earnings prospects. Despite the stock fluctuations, these companies have consistently demonstrated strength in earnings, crowning them as compelling avenues for investment.

(We are reissuing this article to correct a mistake. The original article, issued on November 28, 2023, should no longer be relied upon.)

Uncover a treasure trove of opportunities with Zacks by exploring the latest stock analysis reports, free of charge.

Expect the unexpected and witness how you can supercharge your investments with Zacks’ portfolio services like Surprise Trader, Stocks Under $10, and Technology Innovators, which have set the stage ablaze, closing a whopping 162 positions with double- and triple-digit gains in 2023 alone.

Walk the serene path of financial enlightenment by seizing this opportunity; get first-hand access to diverse analysis reports now.

Discover the pulse of the stock market with the latest recommendations from Zacks Investment Research. Equip yourself with top-notch information to steer your investment journey towards success, and you can start by downloading 7 Best Stocks for the Next 30 Days, free of charge.

Empower your investment decisions by diving deep into the financial vistas with free stock analysis reports, uncovering the hidden gems of the stock market. Unleash your potential by exploring Zacks Investment Research.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.